Literature DB >> 11880967

Increased survival of persons with tuberculosis and human immunodeficiency virus infection, 1991--2000.

Michael K Leonard1, Nina Larsen, Henning Drechsler, Henry Blumberg, Jeffrey L Lennox, Martha Arrellano, Jennifer Filip, C Robert Horsburgh Jr.   

Abstract

To determine factors associated with the occurrence of human immunodeficiency virus (HIV) infection and tuberculosis (TB) disease (HIV-TB) and the associated survival rate, we analyzed patients with HIV-TB at Grady Memorial Hospital, Atlanta, Georgia, from 1991 through 2000. Overall, 644 patients with HIV-TB were seen. The number of HIV-TB cases per year was highest in 1992 (102 cases) and declined to 39 cases in 2000. Over time, patients were more likely to be enrolled in the HIV outpatient clinic (P<.01), but, in 1997, only 21 (51%) of 41 patients were enrolled in HIV-infection care programs and only 9 (22%) of 41 received HAART. The 1-year survival rate for patients with HIV-TB was 58% in 1991, 81% in 1994, and 83% in 1997 (P<.001). The increase in survival for patients with HIV-TB between 1991 and 1994 was likely due to improved TB and HIV therapy. More effective strategies for enrolling and maintaining HIV-TB patients in HIV-infection care programs could further increase survival.

Entities:  

Mesh:

Year:  2002        PMID: 11880967     DOI: 10.1086/339448

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  10 in total

Review 1.  Factors that influence current tuberculosis epidemiology.

Authors:  Juan-Pablo Millet; Antonio Moreno; Laia Fina; Lucía del Baño; Angels Orcau; Patricia García de Olalla; Joan A Caylà
Journal:  Eur Spine J       Date:  2012-05-08       Impact factor: 3.134

2.  A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4⁺ T-cell counts of ≥ 350 cells/μL.

Authors:  M W Nanteza; H Mayanja-Kizza; E Charlebois; P Srikantiah; R Lin; E Mupere; P Mugyenyi; W H Boom; R D Mugerwa; D V Havlir; C C Whalen
Journal:  J Infect Dis       Date:  2011-09-15       Impact factor: 5.226

3.  Patients diagnosed with tuberculosis at death or who died during therapy: association with the human immunodeficiency virus.

Authors:  S M Marks; E Magee; V Robison
Journal:  Int J Tuberc Lung Dis       Date:  2011-04       Impact factor: 2.373

4.  Risk factors for mortality among patients with extrapulmonary tuberculosis at an academic inner-city hospital in the US.

Authors:  Ekaterina V Kourbatova; Michael K Leonard; Javier Romero; Colleen Kraft; Carlos del Rio; Henry M Blumberg
Journal:  Eur J Epidemiol       Date:  2006-10-27       Impact factor: 8.082

5.  Immunization with a DNA vaccine cocktail protects mice lacking CD4 cells against an aerogenic infection with Mycobacterium tuberculosis.

Authors:  Steven C Derrick; Charlene Repique; Philip Snoy; Amy Li Yang; Sheldon Morris
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

6.  Costs of patients hospitalized for multidrug-resistant tuberculosis.

Authors:  S S Rajbhandary; S M Marks; N N Bock
Journal:  Int J Tuberc Lung Dis       Date:  2004-08       Impact factor: 2.373

7.  HIV-specific health care utilization and mortality among tuberculosis/HIV coinfected persons.

Authors:  L Beth Gadkowski; Carol D Hamilton; Myra Allen; Ellen R Fortenberry; Julie Luffman; Elizabeth Zeringue; Jason E Stout
Journal:  AIDS Patient Care STDS       Date:  2009-10       Impact factor: 5.078

Review 8.  Timing of antiretroviral therapy for HIV in the setting of TB treatment.

Authors:  Damani A Piggott; Petros C Karakousis
Journal:  Clin Dev Immunol       Date:  2010-12-27

Review 9.  HIV & immune reconstitution inflammatory syndrome (IRIS).

Authors:  Surendra K Sharma; Manish Soneja
Journal:  Indian J Med Res       Date:  2011-12       Impact factor: 2.375

10.  Duration of anti-tuberculosis therapy and timing of antiretroviral therapy initiation: association with mortality in HIV-related tuberculosis.

Authors:  Claudia P Cortes; Firas H Wehbe; Catherine C McGowan; Bryan E Shepherd; Stephany N Duda; Cathy A Jenkins; Elsa Gonzalez; Gabriela Carriquiry; Mauro Schechter; Denis Padgett; Carina Cesar; Juan Sierra Madero; Jean W Pape; Daniel R Masys; Timothy R Sterling
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.